NVCN news (up 137%). Following a ~ 54.7% rise today, Neovasc (NASDAQ: NVCN) is continuing the momentum into after-hours trading with a gain of ~ 45.9% on the news of a patent win in Europe.
The company has received a decision to grant European patent number EP3400907 titled "sequentially deployed transcatheter mitral valve prosthesis." source: Seeking alpha Significant news in the life of this company. The analysis shows that the price movement of NVCN deviated from the usual "pump and dump" movement and started to accumulate (red square) This assumes that a further increase is expected. It can also be seen that a fractal construction can take place. This phenomenon is important for setting a target price. If the assumption is correct, price movements could rise by an additional 137% from this level. Target price 7.15usd
The company has received a decision to grant European patent number EP3400907 titled "sequentially deployed transcatheter mitral valve prosthesis." source: Seeking alpha Significant news in the life of this company. The analysis shows that the price movement of NVCN deviated from the usual "pump and dump" movement and started to accumulate (red square) This assumes that a further increase is expected. It can also be seen that a fractal construction can take place. This phenomenon is important for setting a target price. If the assumption is correct, price movements could rise by an additional 137% from this level. Target price 7.15usd
Comment:
I delete the analysis.
Comment:
I deleted the NVCN analysis. This was due to the next $ 70 million share issue. Issue price was 2usd. As a result of this issue, the fair value of NVCN decreased to 0.94usd. Therefore, the uncertainty has increased.